Auscann Group Holdings Ltd
ASX:AC8
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Auscann Group Holdings Ltd
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
